0001398432-17-000061.txt : 20170331 0001398432-17-000061.hdr.sgml : 20170331 20170331135739 ACCESSION NUMBER: 0001398432-17-000061 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170331 DATE AS OF CHANGE: 20170331 EFFECTIVENESS DATE: 20170331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRA PHARMA CORP CENTRAL INDEX KEY: 0001119643 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 912021600 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32141 FILM NUMBER: 17729598 BUSINESS ADDRESS: STREET 1: 12538 W. ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 BUSINESS PHONE: (954) 509-0911 MAIL ADDRESS: STREET 1: 12538 W. ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 FORMER COMPANY: FORMER CONFORMED NAME: CYBER VITAMIN COM DATE OF NAME CHANGE: 20000717 NT 10-K 1 i13072.htm NT 10-K



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549


FORM 12b-25

NOTIFICATION OF LATE FILING



(Check One)   [X]  Form 10-K          [_]  Form 20-F          [_]  Form 11-K          [_]  Form 10-Q          [_] Form N-SAR


For Period Ended: December 31, 2016


[_]   Transition Report on Form 10-K

[_]   Transition Report on Form 20-F

[_]   Transition Report on Form 11-K

[_]   Transition Report on Form 10-Q

[_]   Transition Report on Form N-SAR


For the Transition Period Ended: ________________________


Read Instruction (on back page) Before Preparing Form. Please Print or Type.


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:



PART I - REGISTRANT INFORMATION


Nutra Pharma Corp.

Full Name of Registrant

 

 

Former Name if Applicable

 

12538 W. Atlantic Blvd.

Address of Principal Executive Office (Street and Number)

 

Coral Springs, FL 33071

City, State, Zip Code







PART II - RULES 12b-25 (b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


 

 (a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[X]

 (b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

 (c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


PART III - NARRATIVE


State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed).


The Form 10-K could not be filed within the prescribed time because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.


PART IV - OTHER INFORMATION


(1)   Name and telephone number of person to contact in regard to this notification:


Rik J. Deitsch

 

(954)

 

509-0911

(Name)

 

(Area Code)

 

(Telephone No.)


(2)   Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  [X] Yes    [_] No


(3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  [_] Yes    [X] No


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


NUTRA PHARMA CORP.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.


Date:  March 31, 2017

 

By:

/s/ Rik J. Deitsch

 

 

 

Name: Rik J. Deitsch

Title: President